Document is current
Any future updates will be listed below
-
Authors
Neal, Matthew L.
Boyle, Alexa M.
Budge, Kevin M.
Safadi, Fayez F.
Richardson, Jason R.
-
Funding
Funding for this research was provided by:
National Institute of Environmental Health Sciences (R01ES021800, R01ES026057)
National Institute of Neurological Disorders and Stroke (U01NS079249)
Michael J. Fox Foundation for Parkinson's Research (None)
- License Information
-
More Information
Article History
Received: 14 January 2018
Accepted: 21 February 2018
First Online: 8 March 2018
Ethics approval and consent to participate
: All procedures were performed in accordance with National Institutes of Health guidelines for the care and use of laboratory animals with approval by the Institutional Animal Care and Use Committee of Northeast Ohio Medical University. Gene expression data contained no identifying material and were publicly available.
: Not applicable.
: Dr. Safadi has patent and commercialization interests in GPNMB as a therapeutic in bone healing through his company GPN Therapeutics. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
